News & Updates

Show Multimedia Only

CKD patients more prone to tuberculosis

30 Mar 2026 by

Patients with stage 5 chronic kidney disease (CKD5) are at greater risk of developing tuberculosis (TB) than the general population, especially if they are male or receiving dialysis, suggests a Singapore study.

CKD patients more prone to tuberculosis

30 Mar 2026

Antibiotics, low-yield investigations for recurrent UTI prevail in real-world practice

29 Mar 2026 by

Recurrent urinary tract infection (UTI) care in primary and secondary care settings appears to be characterized by low guideline adherence, with a substantial number of women still being treated with antibiotics and subjected to low-yield investigations, according to a study.

Antibiotics, low-yield investigations for recurrent UTI prevail in real-world practice

29 Mar 2026

Severe infections added to list of obesity-related comorbidities

24 Mar 2026 by

Adults with obesity are at increased risk of infection-related hospitalizations and mortality, with a 10th of infection-related deaths estimated to be attributable to obesity, according to a study.

Severe infections added to list of obesity-related comorbidities

24 Mar 2026

GERD, complications up NTM infection risk

23 Mar 2026

Gastroesophageal reflux disease (GERD) and its complications appear to increase the risk of nontuberculous mycobacterium (NTM) infection, suggests a study.

GERD, complications up NTM infection risk

23 Mar 2026

IPF drug extends benefit in post-COVID-19 lung injuries

23 Mar 2026 by

A meta-analysis has shown the efficacy of the antifibrotic agent pirfenidone in preventing the onset and/or progression of interstitial lung abnormalities (ILAs) caused by COVID-19.

IPF drug extends benefit in post-COVID-19 lung injuries

23 Mar 2026

Non-INSTI-based ART combination on the horizon for broad HIV population

20 Mar 2026 by

The investigational combination of doravirine plus islatravir (DOR/ISL)—a fixed-dose, once-daily oral antiretroviral therapy (ART) regimen that does not rely on integrase strand-transfer inhibitors (INSTIs)—is shaping up to be a promising alternative in the management of HIV, showing noninferiority to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in individuals initiating treatment for the first time and maintaining virologic suppression in those switching from various ART regimens, as shown in three phase III studies presented at CROI 2026.

Non-INSTI-based ART combination on the horizon for broad HIV population

20 Mar 2026

How effective are COVID-19 mRNA vaccines in children?

20 Mar 2026 by

Immunization with COVID-19 mRNA vaccines is safe and provides a small protective benefit in children aged 6‒17 years, as shown in a Spain study.

How effective are COVID-19 mRNA vaccines in children?

20 Mar 2026

Novel single-tablet BIC/LEN noninferior to standard of care in PWH

20 Mar 2026 by

A single-tablet regimen (STR) combining bictegravir and lenacapavir (BIC/LEN) was noninferior to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in maintaining virologic suppression among people with HIV (PWH) who are virologically suppressed, according to the ARTISTRY-2 trial presented at CROI 2026.

Novel single-tablet BIC/LEN noninferior to standard of care in PWH

20 Mar 2026

Switch from oral to injectable ART maintains viral suppression, highly acceptable to teens

19 Mar 2026 by

In adolescents with well-controlled HIV, switching from an oral antiretroviral therapy (ART) regimen to the long-acting injectable cabotegravir plus rilpivirine combination appears to be not only safe and efficacious in maintaining viral suppression but also strongly favoured, according to the end-of-study data from the phase I/II IMPAACT 2017 study.

Switch from oral to injectable ART maintains viral suppression, highly acceptable to teens

19 Mar 2026

Pemivibart prevents COVID-19 in people with advanced HIV

18 Mar 2026 by

Individuals living with advanced HIV infection who received pemivibart demonstrate good tolerability, with no cases of RT-PCR-confirmed symptomatic COVID-19 reported through month 6, as shown by the results of a subgroup analysis of the CANOPY study.

Pemivibart prevents COVID-19 in people with advanced HIV

18 Mar 2026

News & Updates

Showing Infectious Diseases articles

Showing

Specialty:

CKD patients more prone to tuberculosis

CKD patients more prone to tuberculosis

Antibiotics, low-yield investigations for recurrent UTI prevail in real-world practice

Antibiotics, low-yield investigations for recurrent UTI prevail in real-world practice

Severe infections added to list of obesity-related comorbidities

Severe infections added to list of obesity-related comorbidities

GERD, complications up NTM infection risk

GERD, complications up NTM infection risk

IPF drug extends benefit in post-COVID-19 lung injuries

IPF drug extends benefit in post-COVID-19 lung injuries

Non-INSTI-based ART combination on the horizon for broad HIV population

Non-INSTI-based ART combination on the horizon for broad HIV population

How effective are COVID-19 mRNA vaccines in children?

How effective are COVID-19 mRNA vaccines in children?

Novel single-tablet BIC/LEN noninferior to standard of care in PWH

Novel single-tablet BIC/LEN noninferior to standard of care in PWH

Switch from oral to injectable ART maintains viral suppression, highly acceptable to teens

Switch from oral to injectable ART maintains viral suppression, highly acceptable to teens

Pemivibart prevents COVID-19 in people with advanced HIV

Pemivibart prevents COVID-19 in people with advanced HIV